NCT00070083View on ClinicalTrials.gov

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2003

Conditions
Lymphoma
Interventions
BIOLOGICAL

oblimersen sodium

BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

prednisone

DRUG

vincristine sulfate

Trial Locations (4)

94305

Stanford Cancer Center at Stanford University Medical Center, Stanford

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

V3V 1Z2

Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey

V5Z 4E6

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

British Columbia Cancer Agency

OTHER

NCT00070083 - Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter